|
Analysis: Europe's crisis spells more pain for drugmakers
Reuters LONDON (Reuters) – Drugmakers are counting the cost of the deepening euro zone crisis, with further austerity-driven price cuts expected in important European markets, including Italy and France. Growing alarm at multiple … Pharma group protests European pricing pain |
 ThirdAge |
Pfizer, Pharmacies Warn of Counterfeit Drug Risks
Fox Business Pfizer (PFE) has launched a new effort in connection with various pharmacies to draw attention to the risks associated with counterfeit prescription drugs. The campaign comes amid growing concerns over illegitimate drugs and a recent … Pfizer: Be wary of counterfeit prescription medicines Pfizer steps up campaign in fight against counterfeit drugs Pfizer Warns About Counterfeit Drugs |
|
AstraZeneca settles one Seroquel XR lawsuit
Reuters (Reuters) – AstraZeneca PLC (AZN.L) said on Thursday it has reached a settlement with privately held Handa Pharmaceuticals LLC that will keep the company from selling a generic form of its Seroquel XR anti-psychotic medicine in the United States until … AstraZeneca Enters Into a Settlement Agreement with Handa Pharmaceuticals … AstraZeneca settles Seroquel patent case with US drug firm Handa Pharmaceuticals AstraZeneca Settles Patent Case With Handa Over Seroquel XR |
|
Horizon Pharma Adds Two New Biopharmaceutical Executives to Its Board of Directors
MarketWatch (press release) NORTHBROOK, IL, Sep 30, 2011 (MARKETWIRE via COMTEX) — Horizon Pharma, Inc. /quotes/zigman/5995570/quotes/nls/hznp HZNP -5.44% today announced the appointments of Michael Grey and Ronald Pauli to the Company's Board of Directors. … |
 ThirdAge |
J&J and Bayer's Xarelto wins where Pfizer drug lost
FierceBiotech The blood-thinner Xarelto has added some upbeat Phase III data to its resume. Bayer ($ BAYN), which is co-developing the drug with Johnson & Johnson ($ JNJ), said the drug met its primary efficacy endpoint in sufferers of acute coronary syndrome. … Bayer, J&J's Xarelto Helped Acute Coronary Syndrome Patients Xarelto Found to Help Angina and Heart Attack Patients Bayer, J&J Blood Thinner Rivaroxaban Met Primary Goal In Phase III Trial |
|
Inovio Pharmaceuticals to Present at Scientific Conferences
Sacramento Bee By Inovio Pharmaceuticals, Inc. BLUE BELL, Pa., Sept. 30, 2011 — /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that scientists, … Inovio Pharmaceuticals to Present at Scientific Conferences Inovio Pharmaceuticals to Present at Scientific Conferences |
 The Star-Ledger – NJ.com |
DEBOARD v. WYETH, INC.
Leagle.com Shelia L. Birnbaum (Skadden, Arps, Slate, Meagher & Flom) of the New York bar, admitted pro hac vice, argued the cause for respondents Wyeth, Inc. and Wyeth Pharmaceuticals, Inc. (Porzio, Bromberg & Newman PC and Ms. Birnbaum, attorneys; … NJ manufacturers cannot be sued for claim that their drugs caused breast … |
|
The Zacks Analyst Blog Highlights: Novartis, Pfizer, AstraZeneca, Roche and …
PR Newswire (press release) CHICAGO, Sept. 29, 2011 /PRNewswire/ — Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. … |
|
How A Black-And-White View Of Pharma Companies Blinds Us To Real Problems
Forbes I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me or follow me on Twitter. For many people, small things … |
 Citybizlist |
Executive appointments at Merck & Co, Actelion and Jazz Pharma
The Pharma Letter US drug giant Merck & Co (NYSE: MRK) has appointed Cuong Viet Do as chief strategy officer, effective October 3. In this position he will be responsible for both developing and executing enterprise-wide strategy and further building connections between … Merck goes outside drug industry for strategy exec, (NYSE: MRK), (NYSE: TEL) |
